作者：
Martin,Stork [1]
;
Sabina,Sevcikova [2]
;
Tomas,Jelinek [3]
;
Jiri,Minarik [4]
;
Jakub,Radocha [5]
;
Tomas,Pika [4]
;
Lenka,Pospisilova [6]
;
Ivan,Spicka [7]
;
Jan,Straub [7]
;
Petr,Pavlicek [8]
;
Alexandra,Jungova [9]
;
Zdenka,Knechtova [1]
;
Viera,Sandecka [1]
;
Vladimir,Maisnar [5]
;
Roman,Hajek [3]
;
Ludek,Pour [1]
作者单位：
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
[1]
Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
[2]
Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, 708 00 Ostrava, Czech Republic.
[3]
Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic.
[4]
4th Department of Medicine-Hematology, Charles University Hospital and Faculty of Medicine, 500 05 Hradec Kralove, Czech Republic.
[5]
Institute of Biostatistics and Analyses, Ltd., 625 00 Brno, Czech Republic.
[6]
1st Medical Department-Clinical Department of Hematology of the First Faculty of Medicine and General Teaching Hospital, Charles University, 128 08 Prague, Czech Republic.
[7]
Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, 100 34 Prague, Czech Republic.
[8]
Hematology and Oncology Department, Charles University Hospital, 323 00 Pilsen, Czech Republic.
[9]
DOI
10.3390/biomedicines10102535
PMID
36289797
发布时间
2023-03-08
换一批
换一批
